Food Effects on Oral Paclitaxel for Advanced Solid Tumors
Part of Cancer, Skin clinical trials.
This study tests how eating food affects how your body absorbs an oral (by-mouth) form of paclitaxel, a common cancer drug, when combined with a new medication called encequidar. The goal is to understand the best way to take this drug combination to treat advanced cancers like breast, lung, gastric, or ovarian cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic solid tumor (breast, gastric, lung, or ovarian cancer) for which paclitaxel treatment makes sense
- Your blood cell counts are healthy enough (adequate white blood cells, platelets, and hemoglobin)
- Your liver and kidney function are adequate based on blood tests
- You can fast (not eat or drink) for 10 hours before and 4 hours after taking the study drug
- You are not pregnant, breastfeeding, or able to become pregnant during the study and for 4 months after
- You are not taking certain medications that interfere with how your body processes this drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares an oral chemo pill (paclitaxel plus encequidar) to the standard IV paclitaxel for people with HER2 negative breast cancer that has spread. It aims to see if the oral option works as well or better and may be more convenient.
This trial tests an oral form of paclitaxel for people with advanced solid tumors, including breast cancer. It aims to see if swallowing the drug is safe and effective when standard treatments no longer work.
This trial tests a combination of two drugs, entinostat and a pill form of paclitaxel, for people with a type of advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if you have already tried several treatments, including hormone therapy with a CDK4/6 inhibitor and a chemotherapy with paclitaxel.
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
This trial tests an oral form of a common chemo drug, paclitaxel, given before surgery for triple-negative breast cancer. It aims to find the best dose and see how well it shrinks tumors.
This trial tests a new form of paclitaxel (a chemotherapy drug) wrapped in tiny fat bubbles called liposomes. It is given directly into an artery that feeds the tumor, which may deliver the drug more effectively to the cancer. The study is for people with advanced solid tumors that can be treated this way, such as stomach, liver, pancreatic, or lung cancers.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.